FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091214805> ?p ?o ?g. }

• W2091214805 endingPage "1786" @default.
• W2091214805 startingPage "1786" @default.
• W2091214805 abstract "<h3>Context</h3>Comparative effectiveness is taking on an increasingly important role in US health care, yet little is known about the availability of comparative efficacy data for drugs at the time of their approval in the United States.<h3>Objective</h3>To quantify the availability of comparative efficacy data for new molecular entities (NMEs) approved in the United States.<h3>Data Sources</h3>Approval packages publicly available through the online database of drug products approved by the US Food and Drug Administration (FDA).<h3>Study Selection</h3>Identification of efficacy studies that supported approval of each NME approved by FDA between 2000 and 2010.<h3>Data Extraction</h3>We determined whether eligible studies were head-to-head active controlled trials and whether the results of such studies were available in the approval packages. We recorded the approved indication, whether the NME was an orphan product, whether the NME had undergone priority review, and whether the control group was a specific active comparator or standard care.<h3>Results</h3>Of 197 NMEs identified that met eligibility criteria, 100 (51% [95% confidence interval {CI}, 44%-58%]) met criteria for having comparative efficacy data available at the time of market authorization. After excluding NMEs designated as orphan products (n = 37) and those approved for indications for which no alternative treatments existed (n = 17), this proportion increased to 70% (95% CI, 62%-77%). The proportions of NMEs with available comparative efficacy data varied widely by therapeutic area, from 33% (95% CI, 9%-67%) for hormones and contraceptives to 89% (95% CI, 56%-99%) for diabetes medications.<h3>Conclusion</h3>Publicly available FDA approval packages contain comparative efficacy data for about half of NMEs recently approved in the United States and for more than two-thirds of NMEs for which alternative treatment options exist. We did not investigate the extent to which available comparative efficacy information is useful for clinical guidance." @default.
• W2091214805 created "2016-06-24" @default.
• W2091214805 creator A5004416630 @default.
• W2091214805 creator A5023512359 @default.
• W2091214805 creator A5059157113 @default.
• W2091214805 creator A5070827222 @default.
• W2091214805 date "2011-05-04" @default.
• W2091214805 modified "2023-10-18" @default.
• W2091214805 title "Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States" @default.
• W2091214805 cites W1965739075 @default.
• W2091214805 cites W1979190970 @default.
• W2091214805 cites W1993985133 @default.
• W2091214805 cites W2031992885 @default.
• W2091214805 cites W2153513854 @default.
• W2091214805 cites W2160667678 @default.
• W2091214805 cites W2167535272 @default.
• W2091214805 cites W2314998369 @default.
• W2091214805 cites W2562329777 @default.
• W2091214805 doi "https://doi.org/10.1001/jama.2011.539" @default.
• W2091214805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21540422" @default.
• W2091214805 hasPublicationYear "2011" @default.
• W2091214805 type Work @default.
• W2091214805 sameAs 2091214805 @default.
• W2091214805 citedByCount "63" @default.
• W2091214805 countsByYear W20912148052012 @default.
• W2091214805 countsByYear W20912148052013 @default.
• W2091214805 countsByYear W20912148052014 @default.
• W2091214805 countsByYear W20912148052015 @default.
• W2091214805 countsByYear W20912148052016 @default.
• W2091214805 countsByYear W20912148052017 @default.
• W2091214805 countsByYear W20912148052018 @default.
• W2091214805 countsByYear W20912148052019 @default.
• W2091214805 countsByYear W20912148052020 @default.
• W2091214805 countsByYear W20912148052021 @default.
• W2091214805 countsByYear W20912148052022 @default.
• W2091214805 countsByYear W20912148052023 @default.
• W2091214805 crossrefType "journal-article" @default.
• W2091214805 hasAuthorship W2091214805A5004416630 @default.
• W2091214805 hasAuthorship W2091214805A5023512359 @default.
• W2091214805 hasAuthorship W2091214805A5059157113 @default.
• W2091214805 hasAuthorship W2091214805A5070827222 @default.
• W2091214805 hasConcept C104863432 @default.
• W2091214805 hasConcept C126322002 @default.
• W2091214805 hasConcept C142724271 @default.
• W2091214805 hasConcept C151730666 @default.
• W2091214805 hasConcept C17744445 @default.
• W2091214805 hasConcept C199539241 @default.
• W2091214805 hasConcept C204787440 @default.
• W2091214805 hasConcept C2777466982 @default.
• W2091214805 hasConcept C2778111679 @default.
• W2091214805 hasConcept C2779343474 @default.
• W2091214805 hasConcept C2779473830 @default.
• W2091214805 hasConcept C3018890749 @default.
• W2091214805 hasConcept C512399662 @default.
• W2091214805 hasConcept C535046627 @default.
• W2091214805 hasConcept C60644358 @default.
• W2091214805 hasConcept C71924100 @default.
• W2091214805 hasConcept C75480439 @default.
• W2091214805 hasConcept C86803240 @default.
• W2091214805 hasConcept C98274493 @default.
• W2091214805 hasConceptScore W2091214805C104863432 @default.
• W2091214805 hasConceptScore W2091214805C126322002 @default.
• W2091214805 hasConceptScore W2091214805C142724271 @default.
• W2091214805 hasConceptScore W2091214805C151730666 @default.
• W2091214805 hasConceptScore W2091214805C17744445 @default.
• W2091214805 hasConceptScore W2091214805C199539241 @default.
• W2091214805 hasConceptScore W2091214805C204787440 @default.
• W2091214805 hasConceptScore W2091214805C2777466982 @default.
• W2091214805 hasConceptScore W2091214805C2778111679 @default.
• W2091214805 hasConceptScore W2091214805C2779343474 @default.
• W2091214805 hasConceptScore W2091214805C2779473830 @default.
• W2091214805 hasConceptScore W2091214805C3018890749 @default.
• W2091214805 hasConceptScore W2091214805C512399662 @default.
• W2091214805 hasConceptScore W2091214805C535046627 @default.
• W2091214805 hasConceptScore W2091214805C60644358 @default.
• W2091214805 hasConceptScore W2091214805C71924100 @default.
• W2091214805 hasConceptScore W2091214805C75480439 @default.
• W2091214805 hasConceptScore W2091214805C86803240 @default.
• W2091214805 hasConceptScore W2091214805C98274493 @default.
• W2091214805 hasIssue "17" @default.
• W2091214805 hasLocation W20912148051 @default.
• W2091214805 hasLocation W20912148052 @default.
• W2091214805 hasOpenAccess W2091214805 @default.
• W2091214805 hasPrimaryLocation W20912148051 @default.
• W2091214805 hasRelatedWork W103825824 @default.
• W2091214805 hasRelatedWork W2082673550 @default.
• W2091214805 hasRelatedWork W2127392282 @default.
• W2091214805 hasRelatedWork W2131520364 @default.
• W2091214805 hasRelatedWork W2426703416 @default.
• W2091214805 hasRelatedWork W2646420130 @default.
• W2091214805 hasRelatedWork W2912386223 @default.
• W2091214805 hasRelatedWork W2971584765 @default.
• W2091214805 hasRelatedWork W4231003731 @default.
• W2091214805 hasRelatedWork W4365815395 @default.
• W2091214805 hasVolume "305" @default.
• W2091214805 isParatext "false" @default.
• W2091214805 isRetracted "false" @default.
• W2091214805 magId "2091214805" @default.

• next